Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc., as noted in the metadata) on September 14, 2017. The filing discloses corporate governance changes, specifically the appointment of a new director to the Company's Board.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a compensatory arrangement for the new director:
- Stock Option Grant: 38,106 shares of common stock.
- Exercise Price: $0.72 per share (based on the closing price on September 13, 2016).
- Vesting Schedule: Three annual installments beginning one year after issuance.
Material Changes
The material change reported is the appointment of Athena Countouriotis, M.D., as a director, effective immediately on September 14, 2017. There are no reported changes to financial performance or operational status in this document.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies. It strictly addresses the appointment of the director and the associated compensatory arrangement. No unusual items were reported.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., not Cardiff Oncology, Inc.
- Confirm the vesting terms of the 38,106 stock options granted to Dr. Countouriotis.
- Review the attached press release (Exhibit 99.1) for additional context on the director's qualifications.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.